Table 1.
Clinical-pathological characteristics of dogs’ cohort.
| Variable | N | CTC-Neg | CTC-Pos | p-Value |
|---|---|---|---|---|
| Breed | ||||
| Purebred | 18 | 11 (61.11%) | 7 (38.89%) | 0.448 |
| Crossbreed | 9 | 4 (44.44%) | 5 (55.56%) | |
| Age (years) | 27 | 10.53 (SD * 1.99) | 11.16 (SD * 2.72) | 0.492 |
| Weight (kg) | 27 | 20.83 (SD * 13.87) | 17.23 (SD * 11.33) | 0.475 |
| Previous surgery | ||||
| Non-surgical candidates | 6 | 3 (50.00%) | 3 (50.00%) | 1.000 |
| Prior surgery | 21 | 12 (57.14%) | 9 (42.86%) | |
| Neutering status | ||||
| Intact | 3 | 2 (66.67%) | 1 (33.33%) | 1.000 |
| Neutered | 24 | 13 (54.17%) | 11 (45.83%) | |
| Grading | ||||
| 1–2 | 8 | 3 (37.50%) | 5 (62.50%) | 0.204 |
| 3 | 16 | 11 (68.75%) | 5 (31.25%) | |
| Inflammatory carcinoma | ||||
| No | 14 | 11 (78.57%) | 3 (21.43%) | 0.035 |
| Yes | 10 | 3 (30.00%) | 7 (70.00%) | |
| Staging | ||||
| III + IV | 10 | 5 (50.00%) | 5 (50.00%) | 0.706 |
| V | 17 | 10 (58.82%) | 7 (41.18%) | |
| Metastatic sites | ||||
| Single | 12 | 6 (50.00%) | 6 (50.00%) | 1.000 |
| Multiple | 14 | 8 (57.14%) | 6 (42.86%) | |
| Oestrogen receptor | ||||
| Negative | 18 | 10 (55.56%) | 8 (44.44%) | 1.000 |
| Positive | 6 | 4 (66.67%) | 2 (33.33%) | |
| HER-2 | ||||
| Negative | 18 | 11 (61.11%) | 7 (38.89%) | 0.665 |
| Positive | 6 | 3 (50.00%) | 3 (50.00%) | |
| Progesterone receptor | ||||
| Negative | 23 | 13 (56.52%) | 10 (43.48%) | na ** |
| Positive | 1 | 1 (100.00%) | 0 (0.00%) |
* SD: Standard Deviation; ** na: not applicable.